Diagnosis of lung cancer – improving survival rates by Athey, V. L. et al.
Diagnosis of lung cancer – improving survival rates
ATHEY, V. L., TOD, A. M., SUCKLING, R. and ROGERS, T. K.
Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/2529/
This document is the author deposited version.  You are advised to consult the 
publisher's version if you wish to cite from it.
Published version
ATHEY, V. L., TOD, A. M., SUCKLING, R. and ROGERS, T. K. (2010). Diagnosis of 
lung cancer – improving survival rates. European oncology, 6 (2), 26-30. 
Repository use policy
Copyright © and Moral Rights for the papers on this site are retained by the 
individual authors and/or other copyright owners. Users may download and/or print 
one copy of any article(s) in SHURA to facilitate their private study or for non-
commercial research. You may not engage in further distribution of the material or 
use it for any profit-making activities or any commercial gain.
Sheffield Hallam University Research Archive
http://shura.shu.ac.uk
 1 
European Oncology 
Diagnosis of Lung Cancer: Improving Survival Rates 
 
Victoria L Athey1,2, Angela M Tod3, Rupert Suckling4, Trevor K Rogers1 
 
1. Doncaster & Bassetlaw Hospitals NHS Foundation Trust 
2. University of Sheffield 
3. Sheffield Hallam University 
4. NHS Doncaster 
 
 
Author for Correspondence 
 
Victoria Athey 
Clinical Research Fellow 
Chest Clinic 
Doncaster Royal Infirmary 
Armthorpe Road 
Doncaster 
DN2 5LT 
 
v.athey@sheffield.ac.uk 
01302 647021 
 
 
Word Count (excluding references) = 2,250 
 
Key Words: Lung Cancer, Early Diagnosis, Screening, Social 
Marketing 
 
 
Abstract 
Lung cancer is a major global health burden with high incidence rates 
but poor long-term survival. Currently the majority of cases are 
diagnosed at an advanced stage when surgical resection is not 
feasible. 
Screening for lung cancer has been a major focus of research for the 
last 40 years. Despite this there is still a lack of evidence to promote 
its use outside of a clinical trial. 
More recently interest has focussed on promoting earlier recognition of 
symptomatic disease among both the general public and primary care 
physicians, in order to encourage more timely investigation and 
referral to secondary care. The hope is that this approach may 
increase the proportion of disease identified in the early stages, 
allowing more surgical resections and improved 5-year survival rates. 
This paper provides an overview of the current evidence base 
regarding early diagnosis of lung cancer and provides some examples 
of innovations to promote this. 
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Background 
 
Lung cancer is a major worldwide health burden, responsible for 1.3 
million deaths in 2004, equating to 2.3% of all deaths. Death rates 
from lung cancer are predicted to continue to rise, with the disease 
being responsible for 2.8% of all deaths (1.67 million) by 20151. 
 
Despite advances in treatment, survival rates from lung cancer in the 
UK have improved by only a few percent in the last 40 years. 5-year 
survival for patients diagnosed between 1991 and 1993 was 5%2. 
Eurocare-43 has highlighted the difference in survival between 
England and other European countries. 5-year survival rates in 
England, for patients diagnosed between 1995 and 1999, were 8.4% 
compared with the average European rate of 12%. These figures are in 
even greater contrast to reported 5-year survival rates in the USA of 
15.7%, for patients diagnosed between 1995 and 20014. Analysis of 
Eurocare-4 also showed that 1-year survival rates in England were 
lower than the European average, probably reflecting poorer access to 
care. This would suggest a particular need to promote earlier 
diagnosis in the UK, in trying to improve survival.  
 
Survival is dependant on disease stage at diagnosis, with marked 
variation between earlier and later stage disease. 5-year survival for 
localised disease is around 49% compared with 2% for disease with 
distant metastases at presentation4. Unfortunately the majority of 
lung cancers are already disseminated at the time of presentation4,5.   
 
 
Screening 
Much interest has focussed on diagnosing lung cancer earlier in order 
to try to improve radical treatment rates and reduce mortality. Initially 
this interest focussed on screening. The first randomised controlled 
trial took place in London in the 1960’s6. This looked at a 6-monthly 
chest-x-ray for 3 years versus a chest x-ray at the beginning and end 
of the 3 year period. Diagnosis and resection rates were higher in the 
group receiving more frequent chest x-rays but lung cancer mortality 
was similar in both groups. Three American studies7 in the 1970’s and 
80’s looked at the use of either chest x-ray alone or in combination 
with sputum cytology. The Mayo Lung Project8 compared 4-monthly 
chest x-ray and sputum cytology to standard care. Participants 
randomised to the standard care arm were advised to have a chest x-
ray and sputum cytology yearly. This showed that resection rates 
increased by 14% (32% to 46%) in the group undergoing screening 
when compared to the group receiving standard care alone, but no 
stage shift was evident. 5-year survival in the screened group reached 
33% in comparison to 15% in the non-screened group.  
 
To avoid confusion by the biases inherent in screening, the ultimate 
proof of benefit is disease-specific mortality. Unfortunately, lung 
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cancer mortality was no different in the 2 groups (3.2/1000 person-
years versus 3.0/1000 person-years). This lack of improvement in 
mortality was also evident in the other two studies: the Johns 
Hopkins8,and Memorial Sloan-Kettering studies9. Both looked at the 
addition of 4-monthly sputum cytology to annual chest x-ray. There 
was also a contemporaneous study10, in Czechoslovakia, comparing 
chest x-ray plus sputum cytology every 6 months, for 3 years, with 
chest x-ray and sputum cytology at the beginning and end of the 3 
years. This study essentially replicated the findings of the Mayo Lung 
Project, with an increased number of cancers detected in the more 
frequently screened group but with no difference in lung cancer 
associated mortality11. None of these studies had a ‘no screening’ 
control group.  
 
Therefore, based on these studies, it would not be possible to 
recommend either chest x-ray or sputum cytology as a screening test 
for lung cancer. Indeed, a Cochrane systematic review12 has suggested 
that more frequent screening with chest x-rays is associated with an 
11% relative increase in lung cancer mortality, when compared with 
less frequent screening. 
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Table 1: Summary of key randomised-controlled trials of the use of chest x-ray with or without sputum cytology for screening for 
lung cancer 
 
Study Intervention Control Sample Key Findings Limitations 
North 
London 
study6 
3 year study of 6-
monthly chest x-ray  
Chest x-ray at the 
start and end of the 
3-year period 
Men aged ≥40 
Current, Ex and 
never smokers 
Volunteers from 
industrial 
establishments 
~25,000 control 
arm and ~29,000 
intervention arm 
Increased diagnosis 
and resection rates in 
the group receiving 
more frequent chest 
x-rays. 
No difference in lung 
cancer mortality 
between the two 
groups. 
Lack of a ‘no-
screening’ group. 
Possibility that 
randomisation was 
inadequate – greater 
number of ex-
smokers in the 
control group, 
greater number of 
men aged 60-64 and 
>70 in the 
intervention group12 
No follow-up beyond 
the 3 years of the 
study. 
Mayo Lung 
Project8 
4-monthly chest x-
ray plus sputum 
cytology 
Standard care 
(patients advised to 
have annual chest x-
ray and sputum 
cytology) 
Male smokers ≥45 
years old, who 
smoked at least 20 
cigarettes/day 
Fit for lobectomy  
Attendees at the 
Mayo clinic 
~4,600 in each arm 
Increased resection 
rates and greater 5-
year survival in the 
‘screened’ group. 
No stage shift evident 
No difference in lung 
cancer mortality 
between the two 
groups. 
Lack of a ‘no-
screening’ group. 
Significant number 
of cancers identified 
in the ‘screened’ 
group were on ‘non-
study’ chest x-rays. 
Contamination of 
the control group by   
non-study x-rays 
(led to detection of 
26% of the identified 
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cancers in this 
group). 
Johns 
Hopkins 
Lung 
Project8,13 
Annual chest x-ray 
plus 4-monthly 
sputum cytology 
Annual chest x-ray Male smokers(≥20 
cigarettes/day) 
aged ≥45 years 
~5,200 in each arm 
No difference in the 
number of lung 
cancers diagnosed, 
resection rates or lung 
cancer mortality 
between the two 
groups. 
Greater number of 
squamous cell 
carcinoma identified 
in the intervention 
group. 
Underpowered to 
evaluate the efficacy 
of sputum cytology 
as a screening test12 
Memorial 
Sloan-
Kettering 
Cancer 
Center Lung 
Cancer 
Screening 
Programme8,9 
Annual chest x-ray 
plus 4-monthly 
sputum cytology 
Annual chest x-ray Male smokers ≥45 
years old. 
Current (or within 
the last year) 
smokers of ≥20 
cigarettes/day  
~5,000 in each arm 
No difference in the 
number of lung 
cancers diagnosed, 
resection rates or lung 
cancer mortality 
between the two 
groups 
Underpowered to 
evaluate the efficacy 
of sputum cytology 
as a screening test12 
Kubík et al 
198610 
3 year study of 6-
monthly chest x-ray 
and sputum 
cytology followed by 
annual chest x-ray 
for 3 years 
Chest x-ray and 
sputum cytology at 
the beginning and 
end of the 3 year 
period, followed by 
annual chest x-ray 
for 3 years 
Men aged 40-64 
Attending the chest 
clinic 
Lifetime cigarette 
consumption of 
>150,000 
cigarettes 
~3,170 men in 
each arm 
Increased rate of 
diagnosis in the more 
frequently screened 
group during years 1-
3. 
No stage shift 
No difference in lung 
cancer mortality 
between the 2 groups 
Lack of a ‘no-
screening’ group 
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Chest x-rays are less sensitive for the detection of lung cancer than 
CT. Evaluation of the chest x-rays taken as part of the Mayo Lung 
Project identified that 90% of peripheral lung cancers and 65-70% of 
central tumours, that were detected by 4-monthly chest x-ray had, in 
retrospect, been visible on previous x-rays14. Interest has therefore 
moved to the use of computed tomography (CT) for screening. This 
was made possible by the advent of low-dose spiral CT, which reduced 
both the radiation dose and scan time15. Early reports showed 
increased rates of detection over chest x-ray, with the vast majority of 
detected tumours being stage I 16,17,18. The largest observational report 
of CT screening is the International Early Lung Cancer Action Project 
(I-ELCAP)19. A total of 31,567 participants, aged over 40 and deemed 
to be at lung cancer risk due to either cigarette smoking or 
occupational exposure, had a baseline CT. All patients had to be fit to 
undergo thoracic surgery, if required. 27,456 repeat scans were 
performed between 7 and 18 months after the previous screening. 479 
cancers were identified, 405 on the initial scan and 74 on annual 
screening. There were 5 interim diagnoses. Overall 85% of tumours 
were clinical stage I with 72% confirmed pathological stage I. 10-year 
lung cancer survival, for all participants, was 80%, increasing to 88% 
in those with clinical stage I disease. 
 
However, a key criticism of CT is that it identifies nodules that will 
ultimately turn out to be non-malignant. During the prevalence screen 
in the I-ELCAP study19, 13% of CTs identified non-calcified nodules 
requiring further investigation, including serial CTs, PET-CT and 
percutaneous biopsy. Only 9.6% of these participants were 
subsequently proven to have lung cancer. Even higher rates of benign 
nodule identification have been quoted in other studies20,21,22,23 and 
up to 20% of invasive procedures following CT screening are for 
benign disease 20,21,23. 
 
An additional concern is overdiagnosis, such that patients receive 
treatment for slowly growing tumours that may never have caused 
them any problems in their lifetime, a phenomenon that is already 
recognised in other screening programmes24,25. Several studies have 
calculated tumour volume doubling times for screen-detected cancers. 
These have shown that many of the screen-identified tumours are 
slow growing, with doubling times well in excess of the 40-70 days 
calculated from epidemiological data of non-screen identified 
cancers26.   
 
At present there is insufficient evidence to recommend low dose CT as 
a screening test for lung cancer, although there are several 
randomised controlled trials currently underway seeking definitively to 
answer this question 27,28,29.  
  
There are several other areas currently under investigation for use as 
screening tests for lung cancer, including narrow band and 
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autofluorescence bronchoscopy. One observational study looked at the 
use of bronchoscopy, along with CT, as a primary tool in 
screening20,30. Volunteer current and former smokers underwent 
sputum induction for quantitative cytometry and CT before being 
offered autofluorescence bronchoscopy. 561 subjects were enrolled in 
the study, with 378 undergoing bronchoscopy. 14 primary lung 
cancers were identified of which 4 (29%) were CT occult and only 
detected by autofluorescence bronchoscopy. All of these CT occult 
cancers were squamous cell carcinomas. Because of the observational 
nature of the study, the significance of the use of this approach on 
mortality is unknown. 
 
Biological tools, such as testing serum for tumour-associated 
antibodies, detection of gene-promoter hypermethylation in sputum 
samples, exhaled breath volatile organic compounds and detection of 
novel proteins in serum or sputum are also in development31. 
Unfortunately, none of these is currently ready for use in clinical 
practice.  
 
At the current time, no form of screening for lung cancer can be 
recommended. 
 
 
Symptom recognition and reporting 
Interest has now switched to looking at whether lung cancer can be 
diagnosed earlier in its natural history by focussing on promoting 
symptom recognition and reporting. 90% of patients are symptomatic 
at the time of diagnosis32, often experiencing multiple 
symptoms33,34,35. Many of those presenting will have been 
symptomatic for many months, with reported delays to healthcare of 
up to 2 years33. Much work has focussed on investigating this, with 
reported median delays from onset of symptoms to presenting to 
health care ranging from 7 to 31 days35,36,37,38,39. Public knowledge of 
lung cancer symptoms generally appears to be poor35,37,40,41. Patients 
often develop symptoms but are unaware that they could be related to 
a sinister cause: it appears that between 50 and 75% of lung cancer 
patients may not be aware of the significance of their symptoms35,37. 
Only when further symptoms develop, or their general health 
deteriorates, will they seek advice33,35. In particular, systemic 
symptoms such as lethargy and weight loss seem to be associated 
with longer delays, whereas haemoptysis tends to prompt a more 
rapid response33,39. 
   
It has also been noted that even those deemed to be at risk of lung 
cancer, predominantly current and ex-smokers, do not always 
perceive themselves to be at risk35,41. Even when patients recognise a 
change in their health, there are many barriers to presentation. 
Themes that have been identified include fear of wasting the doctors 
time, feeling unworthy of treatment - particularly in relation to being a 
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smoker, being unsure as to whether the symptom/change experienced 
is ‘normal’, putting the symptom down to being part of the ageing 
process, minimising symptoms, stoicism and the difficulty of 
separating out current changes in health care from co-morbid 
conditions40,41.  
 
Delays have also been identified once patients present to their primary 
care team, with many patients having to present on more than one 
occasion before onward referral/further investigation. This is despite 
clear advice in the British National Institute for Clinical Excellence 
(NICE) guidelines regarding chest x-ray referral42. The delay from first 
presentation to referral to a respiratory specialist has been reported to 
range from a mean of 34 days38 to 73 days (range 0->175)37,36,39,43,44. 
Bowen & Raynor’s study37 also showed that, of the 76% of patients 
who first consulted their own family doctor, only one third of patients 
were referred following their initial consultation, with a further third 
referred by another doctor in the practice, suggesting a 2nd 
consultation. A Danish study looked at potential reasons for the delay 
in onward referral of symptomatic patients and identified several 
contributing factors. In patients with co-morbid diseases, symptoms 
were often ascribed to this rather than potential lung cancer45. Chest 
x-rays reported as normal were associated with a longer delay, with 
primary care teams being falsely reassured. 25% of lung cancer 
diagnoses in the UK are made during an acute admission, despite the 
patient having presented previously to their primary healthcare team 
with a symptom that could be indicative of lung cancer46. 
 
Improving the early diagnosis of lung cancer in Britain has become a 
government priority, with the formation of the National Awareness and 
Early Detection Initiative (NAEDI), a key component of the 2007 
cancer reform strategy47. This hypothesizes that delays lead to more 
advanced disease at diagnosis with associated poor 1- and 5-year 
survival rates and potentially avoidable deaths. Abdel-Rehman et al 
calculated that if UK survival rates were similar to those in Europe, 
then nearly 1000 deaths/year, within 5 years of the diagnosis of lung 
cancer, could be avoided48.  
 
The NAEDI pathway highlights many areas, which could be targeted 
in order to try to promote earlier diagnosis49. 
 
Figure 1 The NAEDI pathway49 (From Richards 2009) 
 
 
(JPEG file) 
 
 
One such strategy is to use social marketing techniques to raise 
awareness of lung cancer symptoms and to encourage a more timely 
presentation to health care services. Social marketing uses 
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commercial marketing techniques to change individual and 
organisational behaviours and policies50. 
 
Similar approaches have already been used in other cancers, an 
example of which is the West of Scotland Cancer Awareness Project 
(WoSCAP)51. This project used a mass media campaign combined with 
general practice education to raise awareness of the symptoms of oral 
and colorectal cancer. Awareness of symptoms was improved and, in 
those presenting who were aware of the campaign, presentation was 
timelier in 60%. 
 
An initial social marketing pilot has been carried out in lung cancer, 
in Doncaster, the largest metropolitan borough in the UK, which has a 
high rate of lung cancer52,53. And a high rate of social deprivation. The 
social marketing campaign and primary care education programme 
was initially designed as a way of addressing a recognised health 
inequality.  Six areas, covered by eleven general practice surgeries, 
with the highest lung cancer risk, were identified. In these areas, brief 
intervention training was undertaken with the general practitioners, 
practice nurses and local pharmacists. Following this there was a 
public awareness campaign launched comprising leaflets, advertising 
on bus banners and billboards (Figure 2), local media events and 
coughing bus stops. 
 
Figure 2 Poster used on billboards 
 
(JPEG file) 
 
 
This project increased awareness of the importance of seeking medical 
advice for a prolonged cough and resulted in a statistically significant 
increase in chest x-ray referrals. Lung cancer diagnosis rates were 
also increased although this was not at a statistically significant level. 
No stage shift was evident but the numbers at different lung cancer 
stages were too small for subgroup analysis53,54. 
 
If the responses to this campaign could be replicated on a larger scale, 
and people could be encouraged to present earlier with their 
symptoms, then their disease should be identifiable in a more timely 
fashion. In turn this will hopefully increase the number of patients 
suitable for curative treatment as well as impacting on the numbers 
receiving active treatment (chemotherapy and/or radiotherapy). Both 
actions should lead to improved survival of patients with lung cancer. 
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